Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability. The analyst points out that Pyxis’ lead drug, PYX-201, is an ADC that targets Extradomain-B Fibronectin (EDB+FN) in the tumor stroma and releases a toxic payload into the tumor microenvironment. The analyst has initiated with an Overweight rating with a price target of $13. Stephens notes that the ADC technology has shown strong potential, with recent successes boostin…